CN105669519A - Indole compounds and preparation method and application thereof as drug-resistant bacteria resistant drugs - Google Patents

Indole compounds and preparation method and application thereof as drug-resistant bacteria resistant drugs Download PDF

Info

Publication number
CN105669519A
CN105669519A CN201610002989.9A CN201610002989A CN105669519A CN 105669519 A CN105669519 A CN 105669519A CN 201610002989 A CN201610002989 A CN 201610002989A CN 105669519 A CN105669519 A CN 105669519A
Authority
CN
China
Prior art keywords
indole
methoxycarbonyl
methylene
imidazol
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610002989.9A
Other languages
Chinese (zh)
Other versions
CN105669519B (en
Inventor
洪伟
王昊
常喆
李京洋
杨延辉
王瑜
谭晓丽
欧阳溢凡
杨浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Minzu University
Original Assignee
North Minzu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Minzu University filed Critical North Minzu University
Priority to CN201610002989.9A priority Critical patent/CN105669519B/en
Publication of CN105669519A publication Critical patent/CN105669519A/en
Application granted granted Critical
Publication of CN105669519B publication Critical patent/CN105669519B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention discloses indole compounds represented by the general formula defined in the specification and salts and preparation method thereof, corresponding medical uses of the compounds and the salts thereof, and drugs and disinfectants containing the compounds and the salts thereof. A lot of experiments prove that the compounds and the salts thereof have good bacteriostatic and bactericidal activity on MRSA (drug-resistant staphylococcus aureus), MDR K.pneumonia (drug-resistant klebsiella pneumonia), and MDR A.baumanii (drug-resistant acinetobacter baumannii). In the formula, X is methylene, carbonyl or sulfonyl; R1 is fluorine, chlorine, bromine, methoxy acyl, nitro or hydrogen; R2 is methoxyl acyl, (p-methoxyl acyl)phenyl, (p-trifluoro oxy)phenyl, (p-trifluoro)phenyl, (m-methoxy acyl)phenyl, (m-trifluoro oxy)phenyl, (p-fluoro m-chloro)phenyl or hydrogen; and HA is inorganic acid or a part of organic acid with strong acidity, preferably hydrochloric acid or hydrobromic acid.

Description

Indole compound, preparation method and application of indole compound as drug-resistant bacterium resistant drug
Technical Field
The invention relates to the field of chemistry and medical application of compounds, in particular to an indole compound containing indole, aminoguanidine or hydrazinoketone, a salt thereof, a preparation method and medical application of the indole compound as a drug-resistant bacterium drug.
Background
In recent years, various antibiotics are continuously developed and applied to the market and clinic, and particularly, under the requirement of rapidly eliminating infected patients by some medical institutions and medical personnel and patients, large-dose and excessive abnormal use of the antibiotics is increasingly serious. These phenomena, make the development of resistant bacteria against antibacterial agents also rapid: the emergence of methicillin-resistant staphylococcus aureus (MRSA), methicillin-sensitive staphylococcus aureus (MSSA) and the like brings new troubles to clinical antibacterial and anti-infection treatment.
However, infection by pathogenic microorganisms such as bacteria is always one of the important diseases threatening human health. Due to the wide antibacterial spectrum, strong antibacterial activity and wide clinical application of fluoroquinolone medicaments, in recent years, the medicament resistance phenomenon of bacteria to fluoroquinolone medicaments is increasingly severe, and the propagation of medicament-resistant bacteria, the research of medical researchers and medical staff are forced to urgently develop and apply novel medicaments to overcome the problem of severe medicament resistance in the day. Among them, staphylococcus aureus is one of the most common bacteria causing iatrogenic and medical instrument infections: drug-resistant mutant strains such as newly emerging MRSA are extremely resistant to existing antibacterial drugs; klebsiella pneumoniae and Acinetobacter baumannii are typical iatrogenic or conditionally pathogenic bacteria, and Klebsiella pneumoniae can cause diseases such as pneumonia and meningitis; acinetobacter baumannii can cause bacteremia, urinary infection, secondary meningitis, surgical site infection, ventilator-associated pneumonia and the like.
Due to the emergence of the above-mentioned drug-resistant bacteria, conventional infectious diseases that have been controlled to some extent have become increasingly serious, and have attracted serious attention from clinical and microbiologists. The development of new drugs is slow at present, and the existing drugs can not treat drug-resistant bacteria, so that the problems are further aggravated. The development of drug molecules against drug-resistant bacteria with novel structures is a breakthrough to solve this problem.
Disclosure of Invention
The present invention is made to solve the above problems, and provides an indole compound and a salt thereof, a method for producing the indole compound and the salt thereof, a pharmaceutical use of the corresponding indole compound and the salt thereof, and a pharmaceutical and disinfectant containing the indole compound and the salt thereof. The inventor proves that the compound and the salt thereof have good bacteriostatic and bactericidal activity on MRSA (drug-resistant staphylococcus aureus), MDRK.
The invention provides an indole compound, which has a chemical structural general formula as follows:
wherein,
x is methylene, carbonyl or sulfonyl;
r1 is fluorine, chlorine, bromine, methoxyacyl, nitro or hydrogen;
r2 is methoxyacyl, (p-methoxyacyl) phenyl, (p-trifluoroxy) phenyl, (p-trifluoromethyl) phenyl, (m-methoxyacyl) phenyl, (m-trifluoroxy) phenyl, (p-fluoro-m-chloro) phenyl or hydrogen.
In order to obtain better bacteriostatic and bactericidal effects, the indole compound provided by the invention has R1Preferred are p-chloro, p-bromo, p-fluoro, p-methoxyacyl, p-nitrobenzyl, m-methoxyacyl, and m-nitro.
In order to obtain better bacteriostatic and bactericidal effects, the indole compound provided by the invention has R2Preferably 5-methoxyacyl, 6-methoxyacyl, 5- (p-methoxyacyl) phenyl, 5- (p-trifluoroxy) phenyl, 5- (p-trifluoro-yl) phenyl, 5- (m-methoxyacyl) phenyl, 5- (m-trifluoroxy) phenyl, 5- (p-fluoro-m-chloro) phenyl.
The indole compound provided by the invention and the corresponding X, R1、R2And compound numbers are shown in tables 1 and 2 below.
TABLE 1 Compounds of the general formula I
The indole compound of the general formula I is named as:
compound 1: 2- [ (1-p-chlorobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 2: 2- [ (1-p-fluorophenylmethyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 3: 2- [ (1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 4: 2- [ (1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 5: 2- [ (1-p-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 6: 2- [ (1-m-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 7: 2- [ (1-p-chlorobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 8: 2- [ (1-p-fluorophenylmethyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 9: 2- [ (1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 10: 2- [ (1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 11: 2- [ (1-p-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 12: 2- [ (1-m-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 13: 2- [ (1-benzoyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 14: 2- [ (1-benzoyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
compound 15: 2- [ (1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine;
compound 16: 2- [ (1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine;
compound 17: 2- [ (1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine;
compound 18: 2- [ (1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine;
compound 19: 2- [ (1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indole) methylene ] aminoguanidine;
compound 20: 2- [ (1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indole) methylene ] aminoguanidine.
TABLE 2 Compounds of the general formula I
The indole compound of the general formula II is named as:
compound 21: 1-p-chlorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 22: 1-p-fluorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 23: 1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 24: 1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 25: 1-p-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 26: 1-m-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 27: 1-p-chlorobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 28: 1-p-fluorobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 29: 1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 30: 1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 31: 1-p-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 32: 1-m-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 33: 1-benzoyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone;
compound 34: 1-benzoyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone;
compound 35: 1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 36: 1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 37: 1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 38: 1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 39: 1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
compound 40: 1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone.
The invention also provides a salt of an indole compound, which is characterized in that:
the salt is obtained by reacting the indole compound with an inorganic acid or an organic acid, and the structure of the salt is shown as follows:
wherein HA is inorganic acid or organic acid with strong partial acidity;
and X, R1，R2As defined above, namely:
x is methylene, carbonyl or sulfonyl;
r1 is fluorine, chlorine, bromine, methoxyacyl, nitro or hydrogen;
r2 is methoxyacyl, (p-methoxyacyl) phenyl, (p-trifluoroxy) phenyl, (p-trifluoromethyl) phenyl, (m-methoxyacyl) phenyl, (m-trifluoroxy) phenyl, (p-fluoro-m-chloro) phenyl or hydrogen.
Further in order to obtain better bacteriostasis and sterilization effect, R in the composition1Preferred are p-chloro, p-bromo, p-fluoro, p-methoxyacyl, p-nitrobenzyl, m-methoxyacyl, and m-nitro.
Further in order to obtain better bacteriostasis and sterilization effect, R in the composition2Preferably 5-methoxyacyl, 6-methoxyacyl, 5- (p-methoxyacyl) phenyl, 5- (p-trifluoroxy) phenyl, 5- (p-trifluoro-yl) phenyl, 5- (m-methoxyacyl) phenyl, 5- (m-trifluoroxy) phenyl, 5- (p-fluoro-m-chloro) phenyl.
Further, for the preparation process and the use effect, the inorganic acid is any one of sulfuric acid, phosphoric acid, hydrochloric acid and hydrobromic acid, and the organic acid is sulfonic acid.
Hair brushThe salts of the indole compounds provided are preferably hydrochloride or bromide, corresponding to X, R1、R2And compound numbers are shown in tables 3 and 4 below.
TABLE 3 Compounds of the general formula III
The salt name of the indole compound in the general formula III is:
compound 41: 2- [ (1-p-chlorobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 42: 2- [ (1-p-fluorophenylmethyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 43: 2- [ (1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 44: 2- [ (1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 45: 2- [ (1-p-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 46: 2- [ (1-m-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 47: 2- [ (1-p-chlorobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 48: 2- [ (1-p-fluorophenylmethyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 49: 2- [ (1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 50: 2- [ (1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 51: 2- [ (1-p-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 52: 2- [ (1-m-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 53: 2- [ (1-benzoyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 54: 2- [ (1-benzoyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
compound 55: 2- [ (1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
compound 56: 2- [ (1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
compound 57: 2- [ (1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
compound 58: 2- [ (1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
compound 59: 2- [ (1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
compound 60: 2- [ (1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indole) methylene ] aminoguanidine hydrochloride.
TABLE 4 Compounds of the general formula IV
The salt name of the indole compound of the general formula IV is as follows:
compound 61: 1-p-chlorobenzyl-5-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 62: 1-p-fluorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 63: 1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 64: 1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 65: 1-p-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
compound 66: 1-m-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
compound 67: 1-p-chlorobenzyl-6-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 68: 1-p-fluorobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 69: 1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 70: 1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 71: 1-p-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
compound 72: 1-m-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
compound 73: 1-benzoyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 74: 1-benzoyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 75: 1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 76: 1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 77: 1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 78: 1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
compound 79: 1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
compound 80: 1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide.
The invention also provides a drug-resistant bacterium-resistant pharmaceutical composition, which is characterized in that:
the pharmaceutical composition contains the indole compounds of the general formulas I and II or the salts of the indole compounds of the general formulas III and IV and pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials comprise excipients, diluents, stabilizers, flavoring agents and the like, and are mixed according to a conventional pharmaceutical method to prepare solid dosage forms such as tablets, capsules, granules, powder and the like and liquid dosage forms such as syrup, oral liquid and the like.
The amounts of compounds I, II and their salts III, IV administered vary with the age, sex, condition of the patient, etc. In general, the dose for adult humans may be 0.01 to 5000 mg/day, preferably 1 to 1000 mg/day, more preferably 5 to 500 mg/day.
The invention also provides a disinfectant for disinfecting and sterilizing medical instruments or hands, which is characterized in that:
wherein, the pharmaceutical composition contains the indole compounds of the general formulas I and II or the salts of the indole compounds of the general formulas III and IV and a proper solvent, such as water, ethanol or a mixed solvent thereof.
The concentration of the compounds I and II and the salts III and IV thereof in the disinfectant is related to the requirements of disinfection and sterilization, and the disinfection of the surgical instruments is generally carried out at the mass concentration of 0.05-2.0%, preferably 0.1-1.0%, and more preferably 0.5-1.0%.
The application of the indole compounds of the general formulas I and II or the salts of the indole compounds of the general formulas III and IV in the preparation of drugs for resisting drug-resistant bacteria.
The method for preparing the salts of the indole compounds of the formulas (III and IV) is characterized by comprising the steps of mixing and reacting compounds of a general formula (V) and a general formula (VI) in a dry and anhydrous polar solvent to obtain the salts of the indole compounds of the formulas (III and IV); the indole compounds of the formulas (I and II) can be obtained by alkalifying the salts of the indole compounds of the formulas (III and IV) with alkali
Wherein,
X，R1，R2HA HAs the same meaning as above;
i.e. when X in formula (V) is different,
when X is methylene, the intermediate 1- (3-or 4-substituted benzyl) -3-formyl-5 (or 6) -methoxycarbonylindole (3) is prepared by the following reaction scheme:
when X is carboxyl, the intermediate 1-benzoyl-3-formyl-5 (or 6) -methoxycarbonylindole (4) is prepared by the following reaction route:
when X is sulfonyl, the intermediate 1-benzenesulfonyl-3-formyl-5- (3-or 4-substituted phenyl) indole (8) is prepared by the following reaction scheme:
obtaining the above intermediates 3, 4, 8 (i.e. formula V) and reacting them with compounds of formula (VI) to obtain compounds of formula (III, I)
Alkalizing with NaOH solution to pH above 10;
the compounds in the general formulas (IV and II) can be obtained by the same method.
A method for preparing the indole compounds of the formulas (I and II) and the salts of the indole compounds of the formulas (III and IV), wherein the polar solvent is preferably any one of methanol, ethanol, acetonitrile and N, N-dimethylformamide or a mixed solvent thereof.
A process for preparing the indole compounds of the formulae (I, II) and salts of the indole compounds of the formulae (III, IV) mentioned above, wherein the temperature of the mixing reaction is preferably room temperature or reflux temperature.
Pharmacological experiments with the Compounds of the invention
(one) Experimental manipulations
The Minimum Inhibitory Concentration (MIC) is obtained by measuring the in vitro inhibitory activity by a 96-well microplate method, and the Minimum Bactericidal Concentration (MBC) is measured by a blood plate coating method.
(1) Experimental strains
The following 4 common human pathogenic strains were selected as test subjects in this experiment:
staphylococcus aureus, drug-resistant Klebsiella pneumoniae, drug-resistant Acinetobacter baumannii
(2) The experimental method comprises the following steps: in vitro antimicrobial Activity assay for Compounds
Culturing strains: a single colony growing on a Trypticase Soy Broth (TSB) plate is selected to be inoculated in liquid TSB at 37 ℃ and 200rpm for 18h, and a strain culture is obtained for subsequent determination of antibacterial activity.
The antibacterial activity determination method comprises performing antibacterial activity determination of compounds with sterile 96-well plate, performing primary screening of all strains with each compound at 100 μ g/ml concentration in parallel with 3-well plate to obtain primary antibacterial activity, selecting compounds with antibacterial activity at 100 μ g/ml concentration, further performing Minimum Inhibitory Concentration (MIC) determination, adding 2 times concentration culture medium (trypticase soy broth, TSB) diluted drug into each well, synthesizing each obtained positive compound to obtain primary solution with appropriate concentration, diluting with culture medium (2 ×) to obtain double concentration of each compound, adding 200 μ l of each positive compound, and adding 200 μ l of each positive compound into 96-well plateConcentrations of 100.0, 50.0, 25.0, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4, 0.2, 0.1 and 0.05. mu.g/ml control levofloxacin 12 gradients were used to final concentrations of 64.0, 32.0, 16.0, 8.0, 4.0, 2.0, 1.0, 0.5, 0.25, 0.125, 0.063, 0.031 and 0.016. mu.g/ml respectively, followed by addition of a bacterium S.aureus (ATCC29213), MRSA, RK.pUMAUnie and MDRA.baumanii respectively to determine the MIC of each bacterium for each compound, 100. mu.l was inoculated per well and the amount per well was about 1.1 × 10-10 per well5cfu, final volume 200. mu.l per well. Each plate was provided with 2 growth positive control wells containing no antibacterial and two growth negative control wells using distilled water instead of the culture medium, the 96-well plate was capped and sealed with a transparent tape around, and placed in a wet box for static culture at 37 ℃. The absorbance at 600nm was measured at different time points for each well using a microplate reader, with the time points selected to be 0, 24h and 48h, respectively. Wells in which a clear difference between positive and negative growth control wells was observed after 48h were plated on blood agar plates with 1% DMSO as control. Thereby determining the bactericidal status of the drug and obtaining the Minimum Bactericidal Concentration (MBC).
(II) results of the experiment
Results of in vitro bacteriostatic experiments are shown in table 3.
In vitro inhibitory minimum concentration values (MIC in μ g/mL) of the compounds of interest in Table 5.
TABLE 5
Note: s.aureus: staphylococcus aureus bacteria; MRSA: drug-resistant staphylococcus aureus; pneumonia: drug-resistant klebsiella pneumoniae; baumann ii: drug-resistant acinetobacter baumannii; levofloxacin: levofloxacin; vancomycin: vancomycin; -: no experiment was conducted
Table 6 shows the comparison of the in vitro inhibitory and bactericidal minimum concentration values (MIC and MBC in. mu.g/mL) for some compounds.
TABLE 6
Note: MRSA: drug-resistant staphylococcus aureus; pneumonia: drug-resistant klebsiella pneumoniae; baumann ii: drug-resistant acinetobacter baumannii; vancomycin: vancomycin; and 6: greater than or equal to 100 mug/ml; -: no experiment was conducted
Action and Effect of the invention
As can be seen from tables 3 and 4, the salts (hydrochloride, hydrobromide) of the novel indole compounds of the present invention have very good activity against drug-resistant bacteria, wherein the in vitro antibacterial activity of the compounds 41, 47, 55, 56, 57, 58, 61, 68, 75, 77, 78, 79 against drug-resistant bacteria is far better than that of levofloxacin, and particularly, the compounds 41, 47, 61 also have excellent antibacterial activity against drug-resistant klebsiella pneumoniae and drug-resistant acinetobacter baumannii. Therefore, the compound and the salt thereof can be used for preparing medicines for resisting drug-resistant bacteria such as drug-resistant staphylococcus aureus and disinfectants for medical instruments.
Detailed Description
In order to make the technical means, creation features, achievement purposes and effects of the invention easy to understand, the following examples describe the preparation of the compound, compound salt, and the pharmaceutical use and dosage form of the invention in detail.
EXAMPLES preparation of Compounds of general formulae III, I
Preparation of intermediate 1- (3-or 4-substituted benzyl) -3-formyl-5 (or 6) -methoxycarbonylindole 3 in formula V
Preparation of 3-formyl-5 (or 6) -methoxycarbonylindole (2)
5 (or 6) -methoxycarbonylindole (1) and phosphorus oxychloride (POCl) respectively3) The Vilsmeier-Hack reaction is carried out under the condition of dry N, N-dimethyl sulfoxide to generate 3-formyl-5 (or 6) -methoxycarbonyl indole (2)
Preparation of 3-formyl-5 (or 6) -methoxycarbonylindole (2) operating example
Preparation of 3-formyl-5-methoxycarbonylindole
Indole-5-carboxylic acid methyl ester 5.00g (28.57mmol) was added to ultra dry DMF20mL under nitrogen and cooled to 0 ℃ before phosphorus oxychloride 3.62mL (38.86mol) was slowly added dropwise. After 10min at 0 ℃, the reaction was carried out at room temperature for 3 h. Cooling the reaction solution to 0 ℃, adding 60mL of water to quench the reaction, then adjusting the pH of the reaction solution to 10 by using 2M NaOH aqueous solution, continuing stirring for 5min, and heating to 70 ℃ for reaction for 30 min. Cooling the reaction solution to room temperature, carrying out vacuum filtration, and washing a filter cake with water and methanol respectively to obtain a light pink solid with the yield of 89 percent and m.p.231.4-233.0 ℃;1H-NMR(400MHz,DMSO):12.44(brs,1H,NH),9.98(s,1H,CHO),8.77(d,J＝1.2,1H,Ar-H),8.44(s,1H,Ar-H),7.88(dd,J1＝8.4,J2＝1.6,1H,Ar-H),7.61(d,J＝8.8,1H,Ar-H),3.87(s,3H,CH3)；ES-MS204.1(M+H)+。
3-formyl-5 (or 6) -methoxycarbonylindole (2) and substituted benzyl bromide react in the presence of sodium hydride to generate (3)
Preparation of 1- (3-or 4-substituted benzyl) -3-formyl-5 (or 6) -methoxycarbonylindole (3) operating examples
Preparation of 1-p-chlorobenzyl-3-formyl-5-methoxycarbonylindole
Adding 0.50g (2.46mmol) of 3-formyl-5-methoxycarbonylindole into ultra-dry DMSO8mL under the protection of nitrogen, then adding 0.11g (2.71mmol) of sodium hydride, reacting at room temperature for 1h, adding 0.56g (2.71mmol) of p-chlorobenzyl bromide into the reaction liquid, reacting at room temperature for 10h, after the reaction is finished, adding 20mL of saturated ammonium chloride solution into the reaction liquid, extracting with dichloromethane (150mL × 3), washing the organic layer with saturated aqueous sodium chloride solution and water respectively, drying with anhydrous sodium sulfate, performing rotary evaporation and concentration to obtain a crude product, performing column chromatography, and eluting with dichloromethane to obtain 0.42g of a white solid, wherein the yield is 52%, and m.p.160.160.2-160.7 ℃;1H-NMR(400MHz,CDCl3):10.06(s,1H,CHO),9.03(s,1H,Ar-H),8.02(dd,J1＝8.4,J2＝1.6,1H,Ar-H),7.78(s,1H,Ar-H),7.35(d,J＝8.4,2H,Ar-H),7.33(d,J＝8.4,1H,Ar-H),7.10-7.12(d,J＝8.4,2H,Ar-H),5.37(s,2H,CH2),3.95(s,3H,CH3)；ES-MS328.1(M+H)+。
similarly, intermediates 3 with different R1, R2 substituents can be prepared:
the preparation method of the 1-p-fluorobenzyl-3-formyl-5-methoxycarbonylindole adopts 3-formyl-5-methoxycarbonylindole and p-fluorobenzyl bromide as raw materials. The yield is 96 percent, and m.p.153.3-153.9 ℃;1H-NMR(400MHz,CDCl3):10.05(s,1H,CHO),9.02(s,1H,Ar-H),8.03(dd,J1＝8.8,J2＝1.6,1H,Ar-H),7.77(s,1H,Ar-H),7.35(d,J＝8.4,1H,Ar-H),7.17(dd,J1＝8.8,J2＝5.2,2H,Ar-H),7.06(t,J＝8.8,2H,Ar-H),5.36(s,2H,CH2),3.94(s,3H,CH3)；ES-MS312.1(M+H)+。
the preparation method of the 1-p-methoxycarbonylbenzyl-3-formyl-5-methoxycarbonylindole adopts the 3-formyl-5-methoxycarbonylindole and the p-methoxycarbonylbenzyl bromide as raw materials. The yield is 92 percent, and m.p.203.6-204.0 ℃;1H-NMR(400MHz,CDCl3):10.06(s,1H,CHO),9.03(d,J＝1.2,1H,Ar-H),8.03(d,J＝8.4,2H,Ar-H),8.00(dd,J1＝8.8,J2＝1.6,1H,Ar-H),7.81(s,1H,Ar-H),7.30(d,J＝8.8,1H,Ar-H),7.21(d,J＝8.4,2H,Ar-H),5.46(s,2H,CH2),3.94(s,3H,CH3),3.91(s,3H,CH3)；ES-MS352.1(M+H)+。
the preparation method of the 1-m-methoxycarbonylbenzyl-3-formyl-5-methoxycarbonylindole adopts 3-formyl-5-methoxycarbonylindole and m-methoxycarbonylbenzyl bromide as raw materials. The yield is 91 percent, m.p.148.6-149.3 ℃;1H-NMR(400MHz,CDCl3):10.06(s,1H,CHO),9.03(d,J＝1.2,1H,Ar-H),8.02(dd,J1＝8.8,J2＝1.2,2H,Ar-H),7.94(s,1H,Ar-H),7.80(s,1H,Ar-H),7.44(t,J＝8.0,1H,Ar-H),7.34(d,J＝8.8,1H,Ar-H),7.31(d,J＝8.0,1H,Ar-H),5.44(s,2H,CH2),3.94(s,3H,CH3),3.91(s,3H,CH3)；ES-MS352.1(M+H)+。
the preparation method of the 1-p-nitrobenzyl-3-formyl-5-methoxycarbonylindole adopts the 3-formyl-5-methoxycarbonylindole and the p-nitrobenzyl bromide as raw materials. The yield is 86 percent, m.p.219.2-219.6 ℃;1H-NMR(400MHz,DMSO):10.01(s,1H,CHO),8.80(d,J＝1.2,1H,Ar-H),8.66(s,1H,Ar-H),8.21(d,J＝8.8,2H,Ar-H),7.88(dd,J1＝8.4,J2＝1.6,1H,Ar-H),7.69(d,J＝8.4,1H,Ar-H),7.51(d,J＝8.8,2H,Ar-H),5.79(s,2H,CH2),3.87(s,3H,CH3)；ES-MS339.1(M+H)+。
the preparation method of the 1-m-nitrobenzyl-3-formyl-5-methoxycarbonylindole adopts 3-formyl-5-methoxycarbonylindole and m-nitrobenzyl bromide as raw materials. The yield is 71 percent, m.p.190.9-193.9 ℃;1H-NMR(400MHz,CDCl3):10.09(s,1H,CHO),9.04(s,1H,Ar-H),8.21(d,J＝8.4,1H,Ar-H),8.11(s,1H,Ar-H),8.03(dd,J1＝8.8,J2＝1.6,1H,Ar-H),7.85(s,1H,Ar-H),7.55(t,J＝8.0,1H,Ar-H),7.41(d,J＝8.0,1H,Ar-H),7.30(d,J＝8.8Hz,1H,Ar-H),5.52(s,2H,CH2),3.95(s,3H,CH3)；ES-MS339.1(M+H)+。
the preparation of 1-p-chlorobenzyl-3-formyl-6-methoxycarbonylindole adopts 3-formyl-6-methoxycarbonylindole and p-chlorobenzyl bromide asThe raw materials and the method are the same as above. The yield is 64 percent, and m.p.153.1-154.2 ℃;1H-NMR(400MHz,CDCl3):10.03(s,1H,CHO),8.36(d,J＝8.0,1H,Ar-H),8.09(s,1H,Ar-H),8.02(dd,J1＝8.4,J2＝1.6,1H,Ar-H),7.82(s,1H,Ar-H),7.35(d,J＝8.4,2H,Ar-H),7.12-7.14(d,J＝8.4,2H,Ar-H),5.40(s,2H,CH2),3.94(s,3H,CH3)；ES-MS328.1(M+H)+。
the preparation method of the 1-p-fluorobenzyl-3-formyl-6-methoxycarbonylindole adopts 3-formyl-6-methoxycarbonylindole and p-fluorobenzyl bromide as raw materials. The yield is 56 percent, and the m.p.155.6 to 155.7 ℃;1H-NMR(400MHz,CDCl3):10.03(s,1H,CHO),8.35(d,J＝8.4,1H,Ar-H),8.11(s,1H,Ar-H),8.01(dd,J1＝8.4,J2＝1.6,1H,Ar-H),7.81(s,1H,Ar-H),7.20(dd,J1＝8.8,J2＝5.2,2H,Ar-H),7.07(t,J＝8.4,2H,Ar-H),5.40(s,2H,CH2),3.94(s,3H,CH3)；ES-MS312.1(M+H)+。
the preparation method of the 1-p-methoxycarbonylbenzyl-3-formyl-6-methoxycarbonylindole adopts the 3-formyl-6-methoxycarbonylindole and the p-methoxycarbonylbenzyl bromide as raw materials. The yield is 58 percent, and m.p.169.9-171.1 ℃;1H-NMR(400MHz,CDCl3):10.05(s,1H,CHO),8.37(d,J＝8.0,1H,Ar-H),8.07(s,1H,Ar-H),8.03(d,J＝8.4,2H,Ar-H),8.01-8.03(dd,J1＝8.4,J2＝1.2,1H,Ar-H),7.85(s,1H,Ar-H),7.23(d,J＝8.4Hz,2H,Ar-H),5.50(s,2H,CH2),3.93(s,3H,CH3),3.91(s,3H,CH3)；ES-MS352.1(M+H)+。
the preparation method of the 1-m-methoxycarbonylbenzyl-3-formyl-6-methoxycarbonylindole adopts 3-formyl-6-methoxycarbonylindole and m-methoxycarbonylbenzyl bromide as raw materials. The yield is 56 percent, m.p.141.2-141.7 ℃;1H-NMR(400MHz,CDCl3):10.03(s,1H,CHO),8.36(d,J＝8.0,1H,Ar-H),8.10(s,1H,Ar-H),8.02(d,J＝8.0,1H,Ar-H),8.01(dd,J1＝8.0,J2＝1.6,1H,Ar-H),7.94(s,1H,Ar-H),7.84(s,1H,Ar-H),7.45(t,J＝7.6,1H,Ar-H),7.34(d,J＝7.6,1H,Ar-H),5.47(s,2H,CH2),3.93(s,3H,CH3),3.91(s,3H,CH3)；ES-MS352.1(M+H)+。
the preparation method of the 1-p-nitrobenzyl-3-formyl-6-methoxycarbonylindole adopts the 3-formyl-6-methoxycarbonylindole and the p-nitrobenzyl bromide as raw materials. The yield is 80 percent, m.p.184.5-184.9 ℃;1H-NMR(400MHz,CDCl3):10.08(s,1H,CHO),8.39(d,J＝8.0,1H,Ar-H),8.22(d,J＝8.8,2H,Ar-H),8.02-8.04(m,2H,Ar-H),7.89(s,1H,Ar-H),7.30(d,J＝8.8,2H,Ar-H),5.56(s,2H,CH2),3.93(s,3H,CH3)；ES-MS339.1(M+H)+。
the preparation method of the 1-m-nitrobenzyl-3-formyl-6-methoxycarbonylindole adopts 3-formyl-6-methoxycarbonylindole and m-nitrobenzyl bromide as raw materials. The yield is 70 percent, and m.p.153.8-155.3 ℃;1H-NMR(400MHz,CDCl3):10.07(s,1H,CHO),8.38(d,J＝8.4,1H,Ar-H),8.21(dd,J1＝8.4,J2＝1.2,1H,Ar-H),8.10(s,1H,Ar-H),8.05(s,1H,Ar-H),8.03(dd,J1＝8.4,J2＝1.2,1H,Ar-H),7.89(s,1H,Ar-H),7.55(t,J＝8.0,1H,Ar-H),7.42-7.44(d,J＝8.0,1H,Ar-H),5.55(s,2H,CH2),3.93(s,3H,CH3)；ES-MS339.1(M+H)+。
preparation of intermediate 1-benzoyl-3-formyl-5 (or 6) -methoxycarbonylindole of formula V, intermediate 4
3-formyl-5 (or 6) -methoxycarbonylindole (2) and benzoyl chloride react with DMF in the presence of sodium hydride to generate 1-benzoyl-3-formyl-5 (or 6) -methoxycarbonylindole (4)
Preparation of 1-benzoyl-3-formyl-5 (or 6) -methoxycarbonylindole (4) example
Preparation of 1-benzoyl-3-formyl-5-methoxycarbonylindole
Under the protection of argon, 0.10g (0.49mmol) of 3-formyl-5-methoxycarbonylindole was added to ultra-dry DMF2mL, and after cooling to 0 ℃, 0.02g (0.54mmol) of sodium hydride was added and the reaction was carried out at room temperature for 1 h. Then, the reaction mixture was cooled to 0 ℃ and 0.07mL (0.54mmol) of benzoyl chloride was added dropwise to the mixture, followed by reaction at room temperature overnight. After the reaction is finished, pouring the reaction liquid into 100mL of water for standing, performing vacuum filtration to obtain a crude product, and performing column chromatography to obtain an eluent, namely ethyl acetate: petroleum ether is 1: 8 (V: V), 0.11g of a white solid was obtained in a yield of 71%. m.p.172.7-173.3 ℃;1H-NMR(400MHz,CDCl3):10.10(s,1H,CHO),9.00(d,J＝1.2,1H,Ar-H),8.35(d,J＝8.8,1H,Ar-H),8.18(dd,J1＝8.8,J2＝1.6,1H,Ar-H),8.03(s,1H,Ar-H),7.81-7.79(m,2H,Ar-H),7.71(t,J＝7.6,1H,Ar-H),7.61(t,J＝7.6,2H,Ar-H),3.98(s,3H,CH3)；ES-MS308.1(M+H)+。
similarly, intermediates 4 with different R1, R2 substituents can be prepared:
the preparation method of the 1-benzoyl-3-formyl-6-methoxycarbonylindole adopts the 3-formyl-6-methoxycarbonylindole as the raw material. The yield is 66 percent, m.p.176.1-176.4 ℃;1H-NMR(400MHz,CDCl3):10.09(s,1H,CHO),9.00(s,1H,Ar-H),8.38(d,J＝8.0,1H,Ar-H),8.15(dd,J1＝8.4,J2＝1.2,1H,Ar-H),8.08(s,1H,Ar-H),7.81-7.79(m,2H,Ar-H),7.73(t,J＝7.6,1H,Ar-H),7.62(t,J＝7.6,2H,Ar-H),3.97(s,3H,CH3)；ES-MS308.1(M+H)+。
preparation of intermediate 1-benzenesulfonyl-3-formyl-5- (3-or 4-substituted phenyl) indole of formula V intermediate (8)
Preparation of 3-formyl-5-bromoindole (6)
5-bromoindole (5) and phosphorus oxychloride (POCl)3) In the dry state of N, N-bisVilsmeier-Hack reaction is carried out under the condition of methyl sulfoxide to generate 3-formyl-5-bromoindole (6)
Preparation of 3-formyl-5-bromoindole (6) operating example
5.00g (25.5mmol) of 5-bromoindole was added to ultra-dry DMF (20ml) under nitrogen and cooled to 0 ℃ and then 3.22ml (34.68mol) of phosphorus oxychloride was slowly added dropwise. After reacting at 0 ℃ for 10min, the reaction was carried out at room temperature for 3 h. Cooling the reaction solution to 0 ℃, adding water (100ml) to quench the reaction, then adjusting the pH of the reaction solution to 8-9 by using 2M NaOH aqueous solution, continuing stirring for 5min, and heating to 70 ℃ for reaction for 30 min. The reaction solution was cooled to room temperature, filtered under reduced pressure to obtain a filter cake, which was dried to obtain 5.19g of a white solid with a yield of 99%. m.p.203.5-204.3 deg.C;1H-NMR(400MHz,DMSO):12.28(s,1H,NH),9.93(s,1H,CHO),8.35(s,1H,Ar-H),8.21(d,J＝2.0,1H,Ar-H),7.49(d,J＝8.4,1H,Ar-H),7.43(dd,J1＝8.8,J2＝2.0,1H,Ar-H)；ES-MS225.1(M+H)+。
preparation of 1-benzenesulfonyl-3-formyl-5-bromoindole (7)
Reacting 3-formyl-5-bromoindole (6) with benzenesulfonyl chloride under the action of sodium hydride to generate 1-benzenesulfonyl-3-formyl-5-bromoindole (7)
Preparation of 1-benzenesulfonyl-3-formyl-5-bromoindole (7) operating example
Under the protection of nitrogen, adding 2.00g (8.8807mmol) of 3-formyl-5-methoxycarbonylindole into ultra-dry DMSO15ml, then adding 0.392g (9.7706mmol) of sodium hydride, reacting at room temperature for 1h, adding 1.883g (10.664mmol) of benzenesulfonyl chloride into the reaction solution, reacting at room temperature for 18h, after the reaction is finished, adding 100ml of saturated ammonium chloride solution into the reaction solution, extracting with dichloromethane (200ml of × 3), washing the organic layer with saturated sodium chloride solution and water respectively, drying with anhydrous sodium sulfate, concentrating by rotary evaporation to obtain a crude product, recrystallizing with acetone/n-hexane to obtain 2.675g of a white solid, wherein the yield is 83%, m.p.235.2-239.3 ℃;1H-NMR(400MHz,DMSO):10.06(s,1H,CHO),8.96(s,1H,Ar-H),8.22(d,J＝2.0,1H,Ar-H),8.14-8.12(m,2H,Ar-H),7.95(d,J＝8.8,1H,Ar-H),7.81-7.77(m,1H,Ar-H),7.69-7.65(m,2H,Ar-H),7.62(dd,J1＝8.8,J2＝2.0,1H,Ar-H)；ES-MS365.2(M+H)+。
preparation of 1-benzenesulfonyl-3-formyl-5- (3-or 4-substituted phenyl) indole, intermediate (8)
1-benzenesulfonyl-3-formyl-5-bromoindole (7) and substituted phenylboronic acid in [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (Pd (dppf) Cl2) Generates 1-benzenesulfonyl-3-formyl-5- (3-or 4-substituted phenyl) indole (8)
Preparation of 1-benzenesulfonyl-3-formyl-5- (3-or 4-substituted phenyl) indole (8) operating examples
Preparation of 1-benzenesulfonyl-3-formyl-5-p-methoxycarbonylphenylindole
Adding 0.5g (1.37mmol) of 1-benzenesulfonyl-3-formyl-5-bromoindole into 10ml of THF and 10ml of water, then sequentially adding 0.28g (2.055mmol) of potassium carbonate, 0.24g (1.64mmol) of p-methoxycarbonylphenylboronic acid and 8.9mg (0.0137mmol) of 1,1' -bis (di-tert-butylphosphine) ferrocene dichloropalladium, heating to 60 ℃, stirring for reaction for 8 hours, extracting with ethyl acetate (100ml × 3) after the reaction is finished, drying with anhydrous sodium sulfate, carrying out rotary evaporation and concentration to obtain a crude product, carrying out column chromatography, and eluting with ethyl acetate/petroleum ether to obtain 0.62g of a white solid, wherein the yield is 86%, m.p.166.5-166.8 ℃;1H-NMR(400MHz,CDCl3):10.13(s,1H,CHO),8.52(d,J＝2.0,1H,Ar-H),8.27(s,1H,Ar-H),8.11(d,J＝8.4,2H,Ar-H),8.04(d,J＝8.8,1H,Ar-H),8.02-7.99(m,2H,Ar-H),7.70-7.63(m,4H,Ar-H),7.57-7.53(m,2H,Ar-H),3.94(s,3H,OCH3)；ES-MS420.5(M+H)+。
similarly, intermediates 8 with different R1, R2 substituents can be prepared:
the 1-benzenesulfonyl-3-formyl-5-m-methoxycarbonylphenylindole is prepared by adopting 1-benzenesulfonyl-3-formyl-5-bromoindole as a raw material in the same way with the yield of 53 percent. m.p.186.8-187.1 ℃; 1HNMR (400MHz, CDCl)3):10.13(s,1H,CHO),8.50(d,J＝1.6,1H,Ar-H),8.28-8.27(m,2H,Ar-H),8.05-7.99(m,4H,Ar-H),7.83-7.80(m,1H,Ar-H),7.69(dd,J1＝8.8,J2＝2.0,1H,Ar-H),7.66-7.63(m,1H,Ar-H),7.57-7.50(m,3H,Ar-H),3.95(s,3H,OCH3)；ES-MS420.5(M+H)+。
The 1-benzenesulfonyl-3-formyl-5-p-trifluorooxyphenylindole is prepared by using 1-benzenesulfonyl-3-formyl-5-bromoindole as a raw material, wherein the yield is 89% by the same method. m.p.180.4-181.3 deg.C; 1H NMR (400MHz in DMSO):10.12(s,1H, CHO),8.98(s,1H, Ar-H),8.34(d, J ═ 1.6,1H, Ar-H),8.18-8.16(m,2H, Ar-H),8.07(d, J ═ 8.8,1H, Ar-H),7.80-7.75(m,2H, Ar-H),7.69-7.65(m,3H, Ar-H),7.61-7.57(m,2H, Ar-H),7.37(d, J ═ 8.4,1H, Ar-H); ES-MS446.4(M + H)+。
The 1-benzenesulfonyl-3-formyl-5-m-trifluorooxyphenylindole is prepared by using 1-benzenesulfonyl-3-formyl-5-bromoindole as a raw material, wherein the yield is 74 percent. m.p.150.4-151.0 deg.C; 1H-NMR (400MHz, DMSO):10.12(s,1H, CHO),8.98(s,1H, Ar-H),8.33(d, J ═ 1.6,1H, Ar-H),8.18-8.16(m,2H, Ar-H),8.07(d, J ═ 8.8,1H, Ar-H),7.78-7.74(m,4H, Ar-H),7.70-7.66(m,2H, Ar-H),7.45(d, J ═ 8.0,2H, Ar-H); ES-MS446.4(M + H)+。
The 1-benzenesulfonyl-3-formyl-5-p-trifluorophenylindole was prepared by using 1-benzenesulfonyl-3-formyl-5-bromoindole as a starting material in the same manner as above with a yield of 67%. m.p.216.5-216.8 ℃;1H-NMR(400MHz,CDCl3):10.13(s,1H,CHO),8.50(d,J＝1.6,1H,Ar-H),8.28(s,1H,Ar-H),8.05(d,J＝8.8,1H,Ar-H),8.03-8.00(m,2H,Ar-H),7.74-7.68(m,4H,Ar-H),7.68-7.63(m,2H,Ar-H),7.58-7.53(m,2H,Ar-H)；ES-MS430.4(M+H)+。
the 1-benzenesulfonyl-3-formyl-5-p-fluoro m-chlorophenyl indole is prepared by using 1-benzenesulfonyl-3-formyl-5-bromoindole as a raw material in the same manner with the yield of 83 percent. m.p.171.1-171.6 deg.C; 1HNMR (400MHz, CDCl)3):10.12(s,1H,CHO),8.41(d,J＝1.6,1H,Ar-H),8.27(s,1H,Ar-H),8.03-7.99(m,3H,Ar-H),7.67-7.62(m,2H,Ar-H),7.58-7.53(m,3H,Ar-H),7.46(ddd,J1＝8.6,J2＝4.4,J3＝2.41H,Ar-H),7.21(t,J＝8.6,1H,Ar-H)；ES-MS414.9(M+H)+。
After the preparation of the intermediates 3, 4 and 8, the reaction can be carried out with salts of the general formula VI
Preparation of the target Compound III
The intermediate (3), the intermediate (4) or the intermediate (8) respectively reacts with aminoguanidine hydrochloride VI in dry methanol at room temperature to generate a target compound III
Preparation of 2- [ (1-p-chlorobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride (Compound 41 in Table 7) operating example
0.20g (0.61mmol) of 1-p-chlorobenzyl-3-formyl-5-methoxycarbonylindole was added to 5mL of anhydrous methanol, 0.07g (0.61mmol) of aminoguanidine hydrochloride was added thereto, and the reaction mixture was adjusted to pH 3 to 4 with concentrated hydrochloric acid at room temperature, followed by reaction at room temperature for 80 min. After the reaction is finished, adding ether into the reaction liquid, standing to separate out a solid, performing suction filtration under reduced pressure, and washing a filter cake with ether to obtain 0.22g of milky white solid with the yield of 87%. The experimental data for compound 41 and other compounds 42-60 are shown in Table 7.
The compounds 42-52 in Table 7 were prepared using intermediate (3) as the starting material in the same manner as above.
The compounds 53 and 54 in Table 7 were prepared using the intermediate (4) as starting material in the same manner as above.
The compounds 55-60 in Table 7 were prepared using intermediate (8) as the starting material in the same manner as above.
Preparation of the object Compound I
Dissolving or suspending 0.5-1.0g of the obtained target compound (III) powder in 5% -10% of ice-cold NaOH solution, adding 1 volume time of dichloromethane DCM solvent of the NaOH solution, vigorously stirring for 10-30 minutes until the pH value of the upper aqueous phase solution is more than 10 (granular NaOH solid can be properly added), standing for layering, extracting the organic phase by 0.5 volume time of DCM solvent, and concentrating under reduced pressure at the temperature of 30 ℃ until the target compound I is dried.
Table 7 shows the R1, R2 and X group collocation, yield and nuclear magnetic hydrogen spectrum data of the target compound III, which are shown in the attached table 7.
Similarly, by changing the aminoguanidine hydrochloride into sulfate, phosphate, hydrobromide or sulfonate, the corresponding sulfate, phosphate, hydrobromide or sulfonate of the target compound iii can be obtained by using ethanol, acetonitrile, N-dimethylformamide DMF or a mixed solvent thereof as the reaction solvent.
Advantageous effects and effects of the embodiment
The synthesis method of the target compounds i and iii provided by the embodiment has simple steps, is easy to purify by filtration and separation, has high yield and is easy to operate, and is suitable for future industrial production, and the reaction is carried out at normal temperature or under reflux.
EXAMPLES preparation of two-way compounds of formula IV, II
Preparation of the target Compound IV
Respectively carrying out reflux reaction on the intermediate (3), the intermediate (4) or the intermediate (8) and 4, 5-dihydroimidazole-2-hydrazine hydrogen bromide VI in dry methanol to obtain a target compound IV;
preparation of 1-p-chlorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide (Compound 61 in Table 8)
0.05g (0.15mmol) of 1-p-chlorobenzyl-3-formyl-6-methoxycarbonylindole was added to 2mL of anhydrous methanol, and then 0.03g (0.15mmol) of 4, 5-dihydroimidazole-2-hydrazinebromide was added to the reaction mixture, and the mixture was heated to 75 ℃ for reaction. After the reaction is finished, cooling the reaction liquid to room temperature, adding ether, standing to separate out a solid, carrying out suction filtration under reduced pressure, and washing a filter cake with ether to obtain 0.07g of milky white solid with the yield of 87%. The experimental data for compound 61 and other compounds 62-80 are shown in Table 8.
The compounds 62-72 in Table 8 were prepared using intermediate (3) as the starting material in the same manner as above.
The preparation of compounds 73 and 74 in Table 8 was carried out in the same manner as above using intermediate (4) as starting material.
The compounds 75-80 of Table 8 were prepared using intermediate (8) as the starting material in the same manner as above.
Preparation of the target Compound II
Dissolving or suspending 0.5-1.0g of the obtained target compound IV powder in 5% -10% of ice-cold NaOH solution, adding 1 volume time of dichloromethane DCM solvent of the NaOH solution, vigorously stirring for 10-30 minutes until the pH value of the upper aqueous phase solution is more than 10 (granular NaOH solid can be properly added), standing for layering, extracting the organic phase by 0.5 volume time of DCM solvent, and concentrating under reduced pressure at the temperature of 30 ℃ until the target compound II is dried.
Table 8 shows the target compound IV R1, the group matching of R2 and X, the yield and nuclear magnetic hydrogen spectrum data, which are shown in the attached Table 8.
Similarly, the operation is carried out, only the aminoguanidine hydrochloride is changed into sulfate, phosphate, hydrobromide or sulfonate, and the corresponding sulfate, phosphate, hydrobromide or sulfonate of the target compound IV can be obtained by using ethanol, acetonitrile, N-dimethylformamide DMF or a mixed solvent thereof as a reaction solvent.
Advantageous effects and effects of the embodiment
The synthesis method of the target compounds II and IV provided by the embodiment has the advantages of simple steps, reaction at normal temperature or under reflux condition, high yield, easy extraction and purification of products, easy operation and suitability for future industrial production.
EXAMPLE III preparation of sterile injectable powder of the Compound of the invention
1. Prescription:
prescription 1:
250g (calculated by compound) of any one of compound III or IV
1000 pieces are prepared in total
Prescription 2:
500g (based on the compound) of any one of the compounds III or IV
1000 pieces are prepared in total
Prescription 3:
1000g (based on the compound) of any one of the compounds III or IV
1000 pieces are prepared in total
Prescription 4:
2000g (based on the compound) of any one of the compounds III or IV
1000 pieces are prepared in total
2. The preparation process comprises the following steps:
(1) performing aseptic treatment on antibiotic glass bottles, rubber plugs and the like used for preparation;
(2) weighing raw materials according to the prescription (charging after conversion), subpackaging the sterile powder in a subpackaging machine, and detecting the packaging amount at any time;
(3) and (4) plugging, capping, fully inspecting finished products, packaging and warehousing.
EXAMPLE four preparation of sterile lyophilized powder for injection of the Compound of the present invention
1. Prescription:
prescription 1:
2. the preparation process comprises the following steps:
(1) preparing a container, namely performing aseptic treatment on antibiotic vials, rubber plugs and the like used for preparation;
(2) preparing a solution, weighing raw materials according to a prescription (feeding after conversion), stirring and dissolving the raw materials in a container by using 500-800 ml of injection water, and simultaneously adjusting the solubility and the pH value by using 10% hydrochloric acid;
(3) filtering to obtain a semi-stoppered solution, filtering the solution, subpackaging, and semi-stoppered;
(4) freeze-drying, plugging, capping, inspecting the finished product, packaging and warehousing.
EXAMPLE five preparation of tablets of the Compound of the invention
1. Prescription:
prescription 1:
prescription 2:
2. the preparation process comprises the following steps:
(1) pulverizing the raw materials, sieving with 100 mesh sieve, and sieving the rest adjuvants with 100 mesh sieve respectively;
(2) weighing raw materials and auxiliary materials according to the prescription amount;
(3) dissolving hydroxypropyl methylcellulose in water to prepare a 2% aqueous solution for later use;
(4) uniformly mixing one of the compounds I, II, III or IV or B, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose, adding a proper amount of 2% HPMC aqueous solution, and uniformly stirring to prepare a proper soft material;
(5) sieving with 20 mesh sieve to obtain granule;
(6) drying the granules at 60 ℃;
(7) adding magnesium stearate, micropowder silica gel and carboxymethyl starch sodium into the dried granules, sieving with a 18-mesh sieve, grading, and mixing uniformly;
(8) sampling and testing a semi-finished product;
(9) tabletting the tablets according to the assay;
(10) and (6) fully inspecting the finished product, and packaging and warehousing.
EXAMPLE sixty preparation of the Compound disinfectant of the present invention
Dissolving the above compound I or II or III or IV with ethanol water mixed solvent to obtain 0.5% -1.0% solution, adding appropriate antiseptic, stabilizer (ethylene glycol, mannitol, etc.), and packaging.
Advantageous effects and effects of the embodiment
The disinfectants of the target compounds I, II, III and IV provided by the embodiment are easy to produce and manufacture, and can be widely used for disinfection and sterilization of hospital surgical instruments and the like.
Accessories
TABLE 7R 1, R2 and X group collocation, yield, melting point, nuclear magnetic hydrogen spectrum and mass spectrometry data for target compound III
TABLE 8 matching of R1, R2 and X groups, yield, melting point, nuclear magnetic hydrogen spectrum and mass spectrum data for the target compound IV

Claims (10)

1. An indole compound has a chemical structure general formula as follows:
wherein,
x is methylene, carbonyl or sulfonyl;
R1is fluorine, chlorine, bromine, methoxyacyl, nitro or hydrogen;
R2is methoxyacyl, (p-methoxyacyl) benzeneA group (p-trifluoroxy) phenyl, (m-methoxyacyl) phenyl, (m-trifluoroxy) phenyl, (p-fluoro-m-chloro) phenyl or hydrogen.
2. The indole compound of claim 1, wherein:
wherein R is1Is p-chloro, p-bromo, p-fluoro, p-methoxyacyl, p-nitro, m-methoxyacyl, m-nitro.
3. The indole compound of claim 1, wherein:
wherein R is25-methoxyacyl, 6-methoxyacyl, 5- (p-methoxyacyl) phenyl, 5- (p-trifluoroxy) phenyl, 5- (p-trifluoro-phenyl), 5- (m-methoxyacyl) phenyl, 5- (m-trifluoro-oxy) phenyl, 5- (p-fluoro-m-chloro) phenyl.
4. The indole compound of claim 1, wherein:
the compound is selected from:
2- [ (1-p-chlorobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-fluorophenylmethyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-m-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-chlorobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-fluorophenylmethyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-p-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-m-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-benzoyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-benzoyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine;
2- [ (1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine;
2- [ (1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine;
2- [ (1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine;
2- [ (1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine;
2- [ (1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indole) methylene ] aminoguanidine;
2- [ (1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indole) methylene ] aminoguanidine;
1-p-chlorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-fluorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-m-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-chlorobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-fluorobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-p-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-m-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-benzoyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone;
1-benzoyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone;
1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone;
1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinone.
5. A salt of an indole compound characterized by:
the salts are salts (III, IV) obtained by reacting the indole compound of any one of claims 1 to 4 with an inorganic or organic acid, and the structures of the salts are shown as follows:
wherein,
x is methylene, carbonyl or sulfonyl;
R1is fluorine, chlorine, bromine, methoxyacyl, nitro or hydrogen;
R2is methoxyacyl, (p-methoxyacyl) phenyl, (p-trifluoroxy) phenyl, (m-methoxyacyl) phenyl, (m-trifluoroxy) phenyl, (p-fluoro-m-chloro) phenyl or hydrogen;
HA is inorganic acid or organic acid with strong partial acidity.
6. The salt of an indole compound of claim 5, wherein:
wherein, the inorganic acid is any one of sulfuric acid, phosphoric acid, hydrochloric acid and hydrobromic acid, and the organic acid is sulfonic acid.
7. The salt of an indole compound of claim 5, wherein:
the salt of the indole compound is hydrochloride or bromide, and is selected from:
2- [ (1-p-chlorobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-fluorophenylmethyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-m-nitrobenzyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-chlorobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-fluorophenylmethyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-p-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-m-nitrobenzyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzoyl-5-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzoyl-6-methoxycarbonyl-3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
2- [ (1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indole) methylene ] aminoguanidine hydrochloride;
1-p-chlorobenzyl-5-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-p-fluorobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-p-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-m-methoxycarbonylbenzyl-5-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-p-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
1-m-nitrobenzyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
1-p-chlorobenzyl-6-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-p-fluorobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-p-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-m-methoxycarbonylbenzyl-6-methoxycarbonyl-3-indolylal, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-p-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
1-m-nitrobenzyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
1-benzoyl-5-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-benzoyl-6-methoxycarbonyl-3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-benzenesulfonyl-5- (4-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-benzenesulfonyl-5- (3-methoxycarbonylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-benzenesulfonyl-5- (4-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-benzenesulfonyl-5- (3-trifluoromethoxyphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazinoketone hydrogen bromide;
1-benzenesulfonyl-5- (4-trifluoromethylphenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide;
1-benzenesulfonyl-5- (4-fluoro-3-chlorophenyl) -3-indolecarboxaldehyde, (4, 5-dihydro-1H-imidazol-2-yl) hydrazonone hydrogen bromide.
8. A process for the preparation of a salt of an indole of the formula (iii, iv) as defined in any one of claims 5 to 7 and a salt of an indole of the formula (iii, iv) as defined in any one of claims 1 to 4, which comprises reacting a compound of the formula (v) with a compound of the formula (vi) in a dry, anhydrous polar solvent to obtain a salt of an indole of the formula (iii, iv); the indole compounds of the formulas (III and IV) can be obtained by alkalifying the salt of the indole compounds of the formulas (III and IV) with alkali
Wherein,
x is methylene, carbonyl or sulfonyl;
R1is fluorine, chlorine, bromine, methoxyacyl, nitro or hydrogen;
R2is methoxyacyl, (p-methoxyacyl) phenyl, (p-trifluoroxy) phenyl, (m-methoxyacyl) phenyl, (m-trifluoroxy) phenyl, (p-fluoro-m-chloro) phenyl or hydrogen;
HA is inorganic acid or organic acid with strong partial acidity,
the inorganic acid is preferably any one of sulfuric acid, phosphoric acid, hydrochloric acid and hydrobromic acid,
the organic acid is preferably a sulfonic acid.
9. The process according to claim 8 for the preparation of the salts of indoles of formula (iii, iv) as claimed in any one of claims 5 to 7 and of indoles of formula (iii, iv) as claimed in any one of claims 1 to 4, characterized in that:
wherein the polar solvent is any one or a mixed solvent of methanol, ethanol, acetonitrile and N, N-dimethylformamide,
the temperature of the mixing reaction is room temperature or reflux temperature.
10. An anti-drug-resistant bacteria pharmaceutical composition or disinfectant, characterized in that:
wherein the pharmaceutical composition or disinfectant comprises the indole compound according to any one of claims 1 to 4, or a salt of the indole compound according to any one of claims 5 to 7.
CN201610002989.9A 2016-01-04 2016-01-04 Benzazole compounds, preparation method and its application as drug-resistance bacteria medicine Expired - Fee Related CN105669519B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610002989.9A CN105669519B (en) 2016-01-04 2016-01-04 Benzazole compounds, preparation method and its application as drug-resistance bacteria medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610002989.9A CN105669519B (en) 2016-01-04 2016-01-04 Benzazole compounds, preparation method and its application as drug-resistance bacteria medicine

Publications (2)

Publication Number Publication Date
CN105669519A true CN105669519A (en) 2016-06-15
CN105669519B CN105669519B (en) 2018-01-05

Family

ID=56298818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610002989.9A Expired - Fee Related CN105669519B (en) 2016-01-04 2016-01-04 Benzazole compounds, preparation method and its application as drug-resistance bacteria medicine

Country Status (1)

Country Link
CN (1) CN105669519B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107522650A (en) * 2017-09-19 2017-12-29 井冈山大学 N Benzenesulfonylindole contracting amino guanidine antimicrobial compounds and preparation method thereof
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
CN114621214A (en) * 2022-04-25 2022-06-14 宜春学院 Antibacterial Schiff base N-acylate and preparation method and application thereof
CN117185983A (en) * 2023-06-05 2023-12-08 浙江工业大学 Bisoxindole compound, preparation method thereof and application thereof in preparation of antibacterial agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1378542A (en) * 1999-10-08 2002-11-06 史密丝克莱恩比彻姆公司 FAB I inhibitors
CN101652346A (en) * 2007-02-01 2010-02-17 约瑟夫·傅立叶大学 Novel indole derivative, its preparation method with and uses thereof, especially as the purposes of antiseptic-germicide
CN102883602A (en) * 2010-02-16 2013-01-16 Uwm研究基金会有限公司 Methods of reducing virulence in bacteria
CN103958514A (en) * 2011-04-15 2014-07-30 梅琳塔治疗公司 Antimicrobial compounds and methods of making and using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1378542A (en) * 1999-10-08 2002-11-06 史密丝克莱恩比彻姆公司 FAB I inhibitors
CN101652346A (en) * 2007-02-01 2010-02-17 约瑟夫·傅立叶大学 Novel indole derivative, its preparation method with and uses thereof, especially as the purposes of antiseptic-germicide
CN102883602A (en) * 2010-02-16 2013-01-16 Uwm研究基金会有限公司 Methods of reducing virulence in bacteria
CN103958514A (en) * 2011-04-15 2014-07-30 梅琳塔治疗公司 Antimicrobial compounds and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
叶英,等.: "吲哚-6-酰腙类化合物的微波合成及其抗菌活性研究", 《有机化学》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
WO2018189063A1 (en) * 2017-04-10 2018-10-18 F. Hoffmann-La Roche Ag Peptide macrocycles and use thereof in the treatment of bacterial infections
CN110494442A (en) * 2017-04-10 2019-11-22 豪夫迈·罗氏有限公司 The big ring of peptide and its purposes in treatment bacterium infection
JP2020513039A (en) * 2017-04-10 2020-04-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Peptide macrocycles and their use in the treatment of bacterial infections
US11091514B2 (en) 2017-04-10 2021-08-17 Hoffmann-La Roche Inc. Peptide macrocycles and use thereof in the treatment of bacterial infections
JP7155240B2 (en) 2017-04-10 2022-10-18 エフ．ホフマン－ラ ロシュ アーゲー Peptide macrocycles and their use in treating bacterial infections
CN110494442B (en) * 2017-04-10 2023-07-25 豪夫迈·罗氏有限公司 Peptide macrocycles and their use in the treatment of bacterial infections
CN107522650A (en) * 2017-09-19 2017-12-29 井冈山大学 N Benzenesulfonylindole contracting amino guanidine antimicrobial compounds and preparation method thereof
CN114621214A (en) * 2022-04-25 2022-06-14 宜春学院 Antibacterial Schiff base N-acylate and preparation method and application thereof
CN114621214B (en) * 2022-04-25 2024-04-26 宜春学院 Antibacterial Schiff base N-acylate, and preparation method and application thereof
CN117185983A (en) * 2023-06-05 2023-12-08 浙江工业大学 Bisoxindole compound, preparation method thereof and application thereof in preparation of antibacterial agent

Also Published As

Publication number Publication date
CN105669519B (en) 2018-01-05

Similar Documents

Publication Publication Date Title
CN105669519B (en) Benzazole compounds, preparation method and its application as drug-resistance bacteria medicine
EP2428508B9 (en) Diamino heterocyclic carboxamide compound
CN102316735A (en) The micromolecular inhibitor of gangrenosum acne apoptosis
JP2017061578A (en) Organic compound
CN109942546B (en) Quinolone pyrimidine compound and preparation method and application thereof
EA020733B1 (en) Actagardine derivatives
JPH0780842B2 (en) Distamycin derivatives and methods for producing them
CN109574947A (en) The Oxazolidinone derivative and preparation method thereof of the structure of hydrazone containing biaryl
CN105218427B (en) Two amidine analog derivatives containing double amidino groups indoles benzene and its preparation method and application
CN106632133B (en) Thiazole derivative and the preparation method and application thereof
CN110526910B (en) Thiazole orange benzyl quaternary ammonium salt derivative and preparation method and application thereof
CN105367558B (en) Andrographolidume derivative and its preparation method and application
CN105130960B (en) 1,3,5- triazine derivatives and its application
CN113045494B (en) Pyridone derivative and application thereof in preparation of drugs for preventing and/or treating tuberculosis caused by mycobacterium tuberculosis
CN102603738B (en) Stable moxifloxacin hydrochloride compound
CN109851611B (en) Sulfadiazine compound and preparation method and application thereof
WO2021244416A1 (en) Pyridinyl morpholine compound, preparation method therefor, and application thereof
US9920039B2 (en) 1,2,4-Oxadiazol compounds active against gram-positive pathogens
CN109111396B (en) Quinoline aromatic vinyl derivative and preparation method and application thereof
Rajasekaran et al. Synthesis, antitubercular, antibacterial and antioxidant activity of some 2-phenyl-3-substituted quinazolin-4 (3H)-ones
CN110437177A (en) A kind of pleuromutilin derivative and its preparation method and application
CN103304556B (en) Schiff bases compounds containing chromene, Preparation Method And The Use
CN103467448B (en) 7-(3-amino-4-alcoxylimido-1-piperidyl)-1-[(1R, 2S)-2-fluoro-cyclopropyl] quinolone carboxylic acid compounds and preparation methods thereof
CN112209881B (en) Emodin oxazole compound and preparation method and application thereof
CN112194631B (en) Schiff base bridged sulfaimidazole compound and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180105

Termination date: 20200104

CF01 Termination of patent right due to non-payment of annual fee